期刊文献+

B型利钠肽在结缔组织病相关肺动脉高压中的诊断价值 被引量:16

The value of brain natriuretic peptide in connective tissue diseases associated with pulmonary arterialhypertension
原文传递
导出
摘要 目的通过观察结缔组织病(CTD)相关肺动脉高压(PAH)患者外周血B型利钠肽(BNP)和N末端B型利钠肽原(NT—proBNP)的水平,探讨BNP在CTD相关PAH中的诊断价值。方法对2006—2009年北京协和医院收治的30例CTD合并PAH患者进行超声心动图、右心导管检查及外周血BNP和NT—proBNP水平测定。结果(1)30例CTD相关PAH患者全部为女性,年龄(39.5±11.6)岁,均经右心导管检查证实为PAH。患者血BNP水平[(325.2±426.3)(8.0~1590.0)ng/L]、NT—proBNP水平[(1444.9±1651.4)(55.0~7839.6)ng/L]升高。(2)不同程度PAH患者WHO临床功能分级、右心房压(RAP)、右心室舒张末压(RVEDP)、肺毛细血管楔压(PCWP)、肺血管阻力(PYR)、心指数(cI)、混合静脉血氧饱和度(si0:)、左心室舒张末内径(LVEDd)、右房大小、右心室与左心室舒张末内径比值(RV/LV)、三尖瓣跨瓣压差(TGP)、心包积液发生情况、NT—proBNP差异有统计学意义。(3)应用受试者工作特征曲线(ROC)分析NT—proBNP、BNP对重度PAil的诊断价值,其曲线下面积(AUC)分别为0.74、0.64,提示NT—proBNP优于BNP。NT—proBNP为745.2ng/L对区分重度PAH的敏感性为68.8%,特异性为57.1%;BNP为141.5ng/L时的敏感性为62.5%,特异性为64.3%。(4)相关性分析:NT-proBNP与WHO临床功能分级、RAP、RVEDP、平均肺动脉压(MPAP)、PVR呈正相关(r分别为0.55、0.55、0.36、0.53、0.69,P〈0.05),与CI、si0:呈负相关(r分别为-0.58、-0.62,P≤0.001)。BNP与RAP、MPAP、PVR呈正相关(r分别为0.42、0.40、0.61,P〈0.05),与CI、siO,呈负相关(r分别为-0.46、-0.54,P=0.005),与RVEDP、WHO临床功能分级无相关性(r分别为-0.46、-0.54,P〉0.05)。NT-proBNP与LVEDd呈负相关(r=-0.41,P=0.025),与RAl、RA2、RV、RV/LV比值、TGP呈正相关(r分别为0.40、0.53、0.55、0.49、0.45,P〈0.05)。BNP与RAl、RA2、RV、Rv/LV比值、TGP呈正相关(r分别为0.39、0.45、0.37、0.40、0.36,P〈0.05)。NT.proBNP、BNP均与心包积液明显相关(r分别为0.46、0.43,P〈0.05)。结论CTD相关PAH患者血BNP、NT.proBNP均升高,与WHO临床功能分级、血流动力学参数、超声心动图反映右心室功能参数之间有显著的相关性。提示BNP是判断CTD合并PAH严重程度和预后的一种简单、无创和可信的指标。 Objective To explore the potential role of brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in the assessment of patients with connective tissue diseases(CTD) associated pulmonary arterial hypertension (PAH). Methods Thirty patients with CTD
出处 《中华内科杂志》 CAS CSCD 北大核心 2011年第2期102-106,共5页 Chinese Journal of Internal Medicine
基金 “十一五”国家科技支撑计划(2006BAIOIA07 2008BAl59B02) 中华医学会临床医学科研专项资金项目(08010270105) 北京协和医院青年科研基金(I604900)
  • 相关文献

参考文献14

  • 1McLaughlin VV,Archer SL,Badesch DB,et al.ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society,Inc.; and the Pulmonary Hypertension Association.J Am Coll Cardiol,2009,53:1573-1619.
  • 2Condliffe R,Kiely DG,Peacock A J,et al.Connective tissue disease-associated pulmonary arterial hypertension in the modem treatment era.Am J Respir Crit Care Med,2009,179:151-157.
  • 3Wieshammer S,Dreyhaupt J,Basler B,et al.NT-proBNP for pulmonologists:not only a rule-out test for systolic heart failure but also a global marker of heart disease.Respiration,2009,77:370-380.
  • 4Dimitroulas T,Giannakoulas G,Karvounis H,et al.Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension.Semin Arthritis Rheum,2010,39:278-284.
  • 5Casserly B,Klinger JR.Brain natriuretic peptide in pulmonary arterial hypertension:biomarker and potential therapeutic agent.Drug Des Devel Ther,2009,3:269-287.
  • 6冷晓梅,田军伟,艾脉兴,曾小峰,唐福林.自身免疫性疾病并发肺动脉高压83例临床分析[J].中华风湿病学杂志,2006,10(2):97-100. 被引量:22
  • 7Nagaya N,Nishikimi T,Okano Y,et al.Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension.J Am Coll Cardiol,1998,31:202 -208.
  • 8Leuchte HH,Holzapfel M,Baumgartner RA,et al.Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.J Am Coll Cardiol,2004,43:764-770.
  • 9Dimitroulas T,Giannakoulas G,Karvounis H,et al.Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.Int J Cardiol,2007,121:135-137.
  • 10Williams MH,Handler CE,Akram R,et al.Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.Eur Heart J,2006,27:1485-1494.

二级参考文献19

  • 1Simonneau G,Galie N,Rubin LJ,et al.Clinical classification of pulmonary hypertension.J Am Coll Cardiol,2004,43 (Suppl):5-12.
  • 2Farber HW,Loscalzo J.Mechanisms of disease:pulmonary arterial hypertension.New Engl J Med,2004,351:1655-1665.
  • 3Tan EM,Cohen AS,Fries JF,et al.The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE).Arthritis Rheum,1982,25:1271-1277.
  • 4Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee.Preliminary criteria for the classification of sclerosis (scleroderma).Arthritis Rheum,1980,23:581-590.
  • 5Vitali C,Bombardieri S,Moutsopoulos HM,et al.Preliminary criteria for the classification of Sjogren's syndrome.Arthritis Rheum,1993,36:340-347.
  • 6Bohan A,Peter JB.Polymyositis and dermatomyositis (first of two parts).New Engl J Med,1975,292:344-347.
  • 7Wilson WA,Gharavi AE,Koike T,et al.International consensus statement on preliminary classfication criteria for definite antiphospholipid antibody syndrome.Report of an international workshop.Arthritis Rheum,1999,42:1309-1311.
  • 8Sharp GC,Irvin WS,Tan EM.Mixed connective tissue disease:an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).Am J Med,1972,52:148-149.
  • 9Silver RM.Scleroderma-clinical problems:the lungs.Rheum Dis Clin North Am,1996,22:25-40.
  • 10Bolster MB,Silver RM.Lung disease in systemic sclerosis (scleroderma).Baillieres Clin Rheumatol,1993,7:79-97.

共引文献21

同被引文献136

引证文献16

二级引证文献145

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部